EAP Participates in UEMS Spring Council 2025: Key Highlights

EAP Participates in the UEMS Spring Council 25-26 April 2025

The UEMS Spring Council Meeting took place on 25 and 26 April 2025 in Brussels, bringing together medical specialists from across Europe to discuss strategic priorities for the coming years. 

 

The European Academy of Paediatrics (EAP) was proudly represented by Prof. Berthold Koletzko (EAP President) and Dr. Miguel Martins (Portuguese National Delegate).

Key milestones from the meeting included:

📈 Strengthening CME/CPD Collaboration

Ongoing efforts to expand interprofessional CME/CPD activities to better accommodate interdisciplinary healthcare events.

The Council unanimously approved the European Training Requirements (ETR) for Paediatric Haematology and Oncology, an important step forward for paediatric specialty education. The EAP contributed actively to this achievement, following the initial recommendation made at the EAP Winter Meeting 2024 in Brussels.

A new initiative to promote interdisciplinary collaboration, advance research, and develop training in this crucial field. Paediatrics will be actively represented, and the EAP has been invited to nominate experts.

A further important step was the unanimous approval of the new MJC in Palliative Care, which had strong EAP support. This development will now offer an important platform to advance discussions and initiatives focused on Paediatric Palliative Care within a European framework.

A continued increase in accredited webinar packages, highlighting the evolving nature of medical education.

Miguel Martins & Berthold Koletzko
Presentation of the ETR for Paediatric Haematology and Oncology by Miguel Martins

The EAP remains committed to ensuring the voice of paediatrics is strongly represented within the UEMS structures and to advancing standards of care, training, and research across Europe.

close menu icon

Your Enquiries Are Welcome

We will respond to you by Email

""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative:

  • BERTHOLD KOLETZKO
Read more